Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Oct 23 - Oct 28
2 Rybelsus 14 mg: -1.1% HbA1c reduction, -2.3 kg weight loss vs placebo These results confirm oral semaglutide is effective for blood sugar control, though the weight loss is modest compared to injectable options These are different trials with different designs, so a direct comparison of the numbers is limited
Combination therapies : Pairing rapamycin with exercise or other drugs to maximize benefits and minimize risks
Dietary optimisation represents the first-line approach for maintaining adequate B12 status: Encourage consumption of B12-rich foods: meat, poultry, fish, eggs, dairy products For vegetarians and vegans, recommend fortified foods (cereals, plant-based milk alternatives) or supplementation Address any gastrointestinal symptoms that may be limiting dietary intake Supplementation strategies depend on the severity of deficiency and absorption capacity, following British Society of Haematology and BNF guidance: Oral B12 supplementation may be appropriate for mild deficiency or prevention in at-risk individuals with intact absorption, with dosing according to local protocols Intramuscular hydroxocobalamin injections are indicated for confirmed deficiency: With neurological involvement: 1 mg on alternate days until no further improvement, then 1 mg every 2 months Without neurological involvement: 1 mg three times a week for 2 weeks, then 1 mg every 3 months Patient safety advice includes: Contact your GP if you develop persistent tingling, numbness, unusual fatigue, memory problems, or mood changes Inform healthcare providers of all medications, including over-the-counter supplements Attend scheduled blood test appointments for diabetes and nutritional monitoring Do not stop prescribed medications without medical advice Report any suspected side effects to the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or via the Yellow Card app) Healthcare professionals should adopt an individualised approach , considering the patient's complete medication profile, dietary habits, symptom burden, and laboratory findings
The data are limited at this time, but case reports show that people taking GLP-1 meds reported increased energy, reduced pain, and reduced fatigue
These numbers highlight the accelerating investment by pharmaceutical companies in the oral GLP-1 sector as they seek to capture opportunities in the rapidly expanding obesity and metabolic disease markets
